

Conference Paper

In Vitro Antimicrobial Potential of Impatiens Balsamina Flower Against Staphylococcus Aureus, Escherichia Coli and Candida Albicans

Aghnia Fuadatul Inayah, Siti Rofida^{*}, Lilik Yusetyani, Muhammad Erfan, Lintang Alhaj Faulina Dinasty, Selvia Mufidah, Hafidhah Shabrina, Nur Wazilah, Yenny Endah Sari, Nindya Alfa Dicha Agustina Wati, Parista Adellina, Dinda Oni Tsarah Fatimawati Girsang

Department of Pharmacy, Faculty of Health Sciences, University of Muhammadiyah Malang **ORCID**

Siti Rofida: https://orcid.org/0000-0002-2541-9698

Abstract.

Corresponding Author: Siti Rofida; email: rofida79@umm.ac.id

Published 15 September 2022

Publishing services provided by Knowledge E

© Aghnia Fuadatul Inayah et al. This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Selection and Peer-review under the responsibility of the ICMEDH Conference Committee. The search for new drugs to treat cases of infection continues. This is because the microorganisms that cause infection continue to mutate as a form of self-defense which causes resistance to antibiotics. One strategy for finding new drugs is through the exploration of active ingredients derived from plants that have been used empirically by the community. Impatiens balsamina is a plant that has been shown to have antibacterial, antifungal, antipruritic, and anti-allergic characteristics. The ethanol extract of the Impatiens balsamina flower contains secondary metabolites such as naphthoquinones, coumarin derivatives, flavonoids, steroids, quinones, and saponins. This study aimed to obtain the active ingredient of the Impatiens balsamina flower which is used as an herbal medicine in the treatment of infection. A multilevel extraction process was carried out using solvents of different polarity, so that fractions containing nonpolar compounds, semipolar compounds, and polar compounds were obtained. Then, each fraction was tested for antimicrobial potency. Antimicrobial testing in vitro was carried out using the disc diffusion method. The results showed that the secondary metabolites contained in the hexane fraction were terpenoids, flavonoids, polyphenols, and anthraquinone compounds. Secondary metabolites contained in the ethyl acetate fraction were alkaloids, terpenoids, flavonoids, polyphenols, and anthraquinone compounds. Secondary metabolites contained in the ethanol fraction were terpenoids, flavonoids, polyphenols, and anthraquinone compounds. The hexane fraction had the best percentage of inhibition and percentage of effectiveness against Staphylococcus aureus, Escherichia coli, and Candida albicans.

Keywords: antimicrobial, fractionation, Impatiens balsamina L flower, disc diffusion

1. Introduction

Gen Access

Infection is a pathological condition caused by microorganisms such as bacteria, viruses, fungi and protozoa, and can occur in the community or in hospitals. Patients who are being treated in a hospital have a greater risk of contracting an infection than outside

How to cite this article: Aghnia Fuadatul Inayah, Siti Rofida*, Lilik Yusetyani, Muhammad Erfan, Lintang Alhaj Faulina Dinasty, Selvia Mufidah, Hafidhah Shabrina, Nur Wazilah, Yenny Endah Sari, Nindya Alfa Dicha Agustina Wati, Parista Adellina, Dinda Oni Tsarah Fatimawati Girsang, (2022), "In Vitro Antimicrobial Potential of Impatiens Balsamina Flower Against Staphylococcus Aureus, Escherichia Coli and Candida Albicans" in *The International Conference of Medicine and Health (ICMEDH)*, KnE Medicine, pages 405–415. DOI 10.18502/kme.v2i3.11891



the hospital. This can occur as a result of interactions between patients, the environment and microbes. According to Wikansari et al[1]shows that 10 of the 16 inpatient rooms at the "X" hospital in Semarang City have airborne germ numbers exceeding the total germ threshold in the inpatient room. In one hospital in the Sidoarjo area, it was stated that in 2016-2017, the map of germs in the intensive care unit showed the dominance of gram-negative bacteria, namely Proteus vulgaris, Yersinia enterocolitica, Enterobacter aerogenes, Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa [2].

Infections that occur in hospitals and attack patients who are in the process of being treated are known as nosocomial infections or Healthcare Associated Infections (HAIs). The prevalence of nosocomial infections in hospitalized patients is 15%, of which 75% of cases occur in Southeast Asia and Africa [3]. Various efforts have been made by hospitals in overcoming nosocomial infections, namely by washing hands before and after contact with patients; use personal protective equipment such as gloves, masks and other personal protective equipment; carry out decontamination of tools after use in service; sharp tool management; medical and non-medical waste management [4].

Handling in cases of infection is the administration of antibiotic therapy. However, currently some antibiotics are no longer able to overcome cases of infection because there has been antibiotic resistance. This antibiotic resistance occurs because of the free use of antibiotics, so that microorganisms become more resistant to antibiotics. The resistance of microorganisms to antibiotics occurs because they are too often exposed to antibiotics, so that microorganisms undergo mutations to form a layer of biofilms, so that their cell walls are thicker and cannot be penetrated by antibiotics. This mechanism is a defense mechanism for microorganisms to survive[5]. The highest antibiotic resistance against bacteria is found in antibiotics with a beta lactam ring, namely the first and third generation penicillins and cephalosporins [6–8].

This antibiotic resistance if not treated can cause cases of infection to become out of control. The increase in the incidence rate will be very fast, because infection is a contagious disease. Efforts are being made to prevent antibiotic resistance by establishing a policy on the use of antibiotics only for diseases which, according to laboratory data, have been proven to be caused by microorganisms [2, 7, 9].

Another effort is to explore new drugs with plant sources that have been empirically proven to be efficacious as antimicrobials. How many secondary metabolites have been proven to have antimicrobial properties are phenolic compounds such as simple phenols, phenolic acids, quinones, flavones, flavonoids, tannins, coumarins; group of terpenoid compounds and essential oils; and group of alkaloid compounds[10]. KnE Medicine

One of the plants that has been empirically proven to be an antimicrobial is plants Impatiens balsamina L. This plant contains coumarin compounds, flavonoids, guinones, saponins, and steroids [11]. Based on the research conducted by Kusuma et al (2014), that the ethanolic extract of Impatient balsamina L. showed inhibitory activity against Aeromonas hydrophila bacteria with an inhibition zone diameter of 21.4 mm. This antimicrobial activity was higher than that of the ethanol extract of leaves and stems, where the diameter of the inhibition zones were 11.2 mm and 13.7 mm, respectively [12]. According to Budiana et al (2015), thatflower ethanol extract Impatient balsamina L. at concentrations of 20%, 40% and 80% inhibited the growth of Staphylococcus aureus, Pseudomonas aeruginosa, and Eschercihia coli bacteria with inhibition zone diameters of 10.16-17.16 mm, respectively; 10.33-17.16 mm; and 10.16-19.00 mm [13]. According to Sugiati (1996) the test showed the inhibitory power of Impatiens balsamina L. flower infusion on the growth of Candida albicans at a concentration of 60% equivalent to a ketoconazole solution of 4.8927 g/ml, a concentration of 70% equivalent to a ketoconazole solution of 7.1865 g/ml, and a concentration of 7.1865 g/ml. 80% equivalent to 9.6876 g/ml ketoconazole solution.

2. Method

The type of research used in this research is experimental research. The research will be conducted for 2 consecutive years. The stages of activities carried out in the first year include:

- 1. Preparation of dried simplicia from Impatient balsamina L.
- 2. Graded extraction of from the flower Impatient balsamina L.
- 3. In vitro antimicrobial activity testing

2.1. Tools and Materials

2.1.1. Plant Material

Flower Impatiens balsamina L. used in this study is a purple flower. Interest simplicia obtained fromTrenggana market, Penatih village, Denpasar city, Bali. The interest has been terminated at UPT Materia Medika, East Java Provincial Government with number 074/117/102.7/2017.



2.1.2. Chemicals

Hexan, ethyl acetate, Ethanol, DMSO, dragendorf, anisaldehyd-sulfuric acid, FeCl3, KOH, and H2SO4 10%, Erythromycin, chloramphenicol, Nystatin, Aquadest, TLC plate silica gel F254

2.1.3. Bacterial Strains and Growth Media

Staphylococcus aueus, Escherichia coli, and *Candida albicans* which has been identified in the biomedical and microbiology laboratory Faculty of Medicine University of Muhammadiyah Malang, Mueller Hinton broth, Mueller Hinton Agar.

2.2. Work procedures

2.2.1. Metabolite profiling of Impatiens balsamina L.

The metabolite profile of hexsan, ethyl acetate, and ethanol fraction from *Impatiens balsamina* L. was carried out using thin layer chromatography. The stationary phase used silica gel F254 and mobile phase of ethyl acetate:chloroform = 3:7. Chromatogram profiles were observed with UV wavelength 254 nm and 365 nm. Metabolite compounds were detected by dragendorf, anisaldehyd-sulfuric acid, FeCl3, KOH, and H2SO4 10% reagent.

2.2.2. Antibacterial Assay

Antibacterial activity of the hexane, ethyl acetate, and ethanol fraction from *Impatiens balsamina* L. was tested using the disc diffusion method. *Staphylococcus aureus*, *Escherichia coli*, and *Candida albicans* were grown on Mueller Hinton Agar. Solution of the substance with a concentration of 80 mg/mL, 120 mg/mL and 160mg/mL each of 50 microliters was absorbed onto the paper disc. Samples on paper discs were diffused on bacterial growth medium and incubated at 37°C for 24 hours. The clear zone around the paper disc indicates inhibition of bacterial growth. The inhibition activity was calculated by equation :

Inhibition activity (%) =
$$\frac{d2 - d1}{d1} \times 100\%(1)$$

where d1=diameter of paper disc (6mm); d2=diameter of inhibition zone ofhexsan, ethyl acetate, and ethanol fraction of *Impatiens balsamina* L. (mm)



The effectiveness of hexsan, ethyl acetate, and ethanol fraction of Impatiens balsamina L. as antibacterial on Staphylococcus aueus, Escherichia coli, and Candida albicans compared to the positive control control Erythromycin, chloramphenicol, Nystatin, can be calculated by the equation:

Antibacterial effectiveness(%) =
$$\frac{d2}{d3}x100\%(2)$$

Where d2= diameter of inhibition zone of hexsan, ethyl acetate, and ethanol fraction of Impatiens balsamina L. (mm); d3=diameter of inhibition of positive control Erythromycin, chloramphenicol, Nystatin, (mm)

3. Result

3.1. The results of making dried simplicia flowers Impatiens balsamina L.

Flower Impatiens balsamina L. used in this study is a purple flower. Interest simplicia obtained from Trenggana market, Penatih, Denpasar, Bali. The interest has been terminated at UPT Materia Medika, East Java Provincial Government with number 074/117/102.7/2017. Fresh flower simplicia, flower simplicia that has gone through the drying process using an oven at 40°C for 3 days, and the mashed simplicia can be seen in Figure 1.



Figure 1: Flower I.balsaminaL. wet (A), flowerI.balsaminaL. dry (B), flower simplicia powderI.balsaminaL. (C).

3.2. The results of graded extraction from the flower Impatiens balsamina L.

Extraction of chemical compounds from powder flower Impatiens balsamina L. using the kinetic maceration method for 4 hours at a speed of 400 rpm. Extraction is carried

out in stages using solvents that have different polarities, namely by using hexane, ethyl acetate, and ethanol as solvents. The results of the multilevel extraction of *Impatiens balsamina* L. flower simplicia powder can be seen in Table 1.

TABLE 1: Flower fractionation yield Impatiens balsamina L.

No	Test Material	% Randemen
1	N-hexane fraction	5.53
2	Ethylacetate Fraction	31.08
3	Ethanol Fraction	21.20

3.3. Chemical compound screening results Fraction of Impatiens balsamina L.

Chemical compounds extracted in each fraction were identified using the TLC technique. Hexane fraction using fsilica gel stationary ase F254; mobile phase hexane:ethyl acetate+formic acid in a ratio of 7.5:2.5+1 drops. Ethyl acetate fraction using fsilica gel stationary ase F254; mobile phasehexane:ethyl acetateby comparison2:8. Ethanol fraction using fsilica gel stationary ase F254; mobile phaseethyl acetate:ethanolby comparison8:2. The results of chemical screening for each fraction can be seen in Table 2.

3.4. Inhibitory activity and antibacterial effectiveness Farction of Impatiens balsamina L.

Some microbes such as bacteria, fungi, and viruses have pathogenic properties in humans. Some of these microbes are *Staphylococcus aureus*, *Escherichia coli*, and *Candida albicans*. Infections from these microbes are given therapy in the form of antibiotics or antifungals [14–17]. Disk diffusion antibiotic susceptibility testing are the qualitative evaluation of tolerance that can be done by the number of colonies inside a typical inhibition zone [18, 19]. The results of the disk diffusion measurement showed that some fractions have good inhibition. This can be seen from the results of the inhibition zone as shown in Table 3 [20, 21]. The data then obtained the inhibitory activity and antibacterial effectiveness. In Table 4, it can be seen that based on the percentage of the hexane fraction, it appears to have better inhibition. Thus, *Impatiens balsamina* L. interest in the hexane fraction can be maximized to develop the discovery of potent antimicrobial compounds.

Test Material	Compound	Stain Viewer	Stain Color	Rf	Information
Hexan Faction	Alkaloids	Dragendor	-	-	-
	Terpenoids	Anisaldehyde- sulfuric acid	Purple	0.37	+
				0.64	
				0.91	
	Flavonoids	Sulfuric acid 10%	Intensive Yellow	0.51	+
	Polyphenol	FeCl3	Black	0	+
	anthraquinon	«KOH 10%	Orange/red	0.3	+
Ethyl acetate fraction	Alkaloids	Dragendor	orange	0.46	+
			orange	0.06	
	Terpenoids	Anisaldehyde- sulfuric acid	Purple	0.96	+
				0.85	
				0.41	
	Flavonoids	Sulfuric acid 10%	Intensive Yellow	0.69	+
	Polyphenol	FeCl3	Black	0.84	+
				0.13	
	anthraquinon	«КОН 10%	Green	0.84	+
			Yellow brown	0.84	
			Red	0.37	
			Yellow brown	0.09	
Ethanol Fraction	Alkaloids	Dragendor	-	-	-
	Terpenoids	Anisaldehyde- sulfuric acid	Purple	0.31	+
	Flavonoids	Sulfuric acid 10%	Intensive Yellow	0.43	+
				0.87	
	Polyphenol	FeCl3	Black	0.32	+
	anthraquinon	KOH 10%	Yellow	0.50	+

TABLE 2: Screening of chemical compounds from the flower fraction Impatiens balsamina L.

4. Conclusion

In the study of antimicrobial testing of the *Impatiens balsamina* L. flower fraction, it can be concluded that The secondary metabolites contained in the hexane fraction are terpenoids, flavonoids, polyphenols and anthraquinone compounds. The secondary metabolites contained in the ethylacetate fraction are alkaloids, terpenoids, flavonoids, polyphenols and anthraquinone compounds. The secondary metabolites contained in the ethylacetate fraction are alkaloids, terpenoids, flavonoids, polyphenols and anthraquinone compounds.

Test Material	Microorganisms	Concentration (mg/disc disc)	Inhibition Zone Diam- eter (mm)			Average±SD
			1	2	3	
Hexan Faction	Staphylococcus aureus	4	12.0	10.5	10.0	10.8 <u>±</u> 0.9
		2	9.0	8.0	8.3	8.4±0.4
		1	7.0	7.0	6.5	6.8±0.2
	Escherichia coli	4	8.83	9.2	9.2	9.1±0.2
		2	8.3	8.3	8.3	8.3±0
		1	6.8	6.8	6.2	6.6±0.3
	Candida albicans	4	21.0	21.75	19.5	20.8 <u>+</u> 0.9
		2	11.2	11.5	10.8	11.2 <u>+</u> 0.3
		1	10.8	10.5	9.00	10.1 <u>+</u> 0.8
KN	Tween 80	5%	-	-	-	
Ethyl acetate fraction	Staphylococcus aureus	4	11.7	10.7	9.8	10.7±0.8
		2	10.0	8.3	8.3	8.9±0.8
		1	9.0	8.2	8.2	8.5±0.4
	Escherichia coli	16	9.5	10.5	10.9	10.3 <u>+</u> 0.6
		8	8.2	8.9	8.8	8.6±0.3
		4	7.2	8.4	7.9	7.8 <u>+</u> 0.5
	Candida albicans	16	19.3	19.3	17.3	18.6 <u>+</u> 0.9
		8	18.5	19.0	16.3	17.9±1.2
		4	10.2	10.2	7.7	9.4 <u>+</u> 1.2
KN	Tween 80	5%	-	-	-	
Ethanol Fraction	Staphylococcus aureus	40	19.5	19.0	19.5	19.3 <u>+</u> 0.2
		20	14.8	17.2	16.0	16.0 <u>+</u> 0.9
		10	10.8	13.8	12.4	12.3 <u>+</u> 1.2
	Escherichia coli	40	7.6	7.5	7.5	7.5 <u>+</u> 0.1
		20	7	6.8	7	6.9±0.1
		10	6.7	6.7	6.7	6.7±0
	Candida albicans	1	13.8	11.0	12.5	12.4 <u>+</u> 1.1
		0.5	10.3	10.5	10.2	10.3 <u>+</u> 0.1
		0.25	6.7	9.8	8.3	8.3±1.2
KN	DMSO	1%	-	-	-	
Erythromycin	Staphylococcus aureus	15 g	27.7	26.0	27.2	26.9 <u>±</u> 0.7
			24.7	23.8	24.0	24.2 <u>+</u> 0.4
			24.5	25.2	26.5	25.4 <u>+</u> 0.8
Nystatin	Candida albicans	2000 IU	16.5	15.0	17.4	16.3 <u>+</u> 0.9
			11.0	14.8	12.7	12.8 <u>+</u> 1.6
			16.2	14.3	15.5	15.3 <u>+</u> 0.8
Chloramphenic	Escherichia coli	30 g	23.3	22.7	22.2	22.7 <u>±</u> 0.4
			25.4	26.5	29.8	27.2 <u>+</u> 1.9
			26.0	25.8	26.7	26.2 <u>+</u> 0.4

TABLE 3: Impatiens balsamina L. Antimicrobial Test Results flower fraction.

the ethanol fraction are terpenoids, flavonoids, polyphenols and anthraquinone compounds. The hexane fraction has the best percentage of inhibition and percentage of effectiveness against bacteria *Staphylococcus aureus*, *Escherichia coli* and *Candida albicans*.

Sample	Microorganisms	Concentration	Inhibition Percentage	Antimicrobial Effectiveness Percentage
Hexan Faction	Staphylococcus aureus	4	80.6	44.8
		2	40.6	34.8
		1	13.9	28.2
	Escherichia coli	4	51.3	34.6
		2	38.3	31.7
		1	10.0	25.2
	Candida albicans	4	245.8	135.6
		2	86.1	73.0
		1	68.3	66.0
Ethyl acetate fraction	Staphylococcus aureus	4	78.9	44.4
		2	47.8	36.6
		1	41.1	35.0
	Escherichia coli	16	71.7	39.3
		8	43.9	33.0
		4	30.6	29.9
	Candida albicans	16	210.6	121.8
		8	198.9	117.2
		4	56.1	61.2
Ethanol Fraction	Staphylococcus aureus	40	222.2	79.9
		20	166.7	66.1
		10	105.6	51.0
	Escherichia coli	40	25.6	28.8
		20	15.6	26.5
		10	11.7	25.6
	Candida albicans	1	107.2	81.3
		0.5	72.2	67.5
		0.25	37.8	54.0

TABLE 4: Percentage of inhibitory activity and antimicrobial effectiveness of flower fraction Impatiens balsamina L.

References

- [1] (Nurvita) Wikansari, "Pemeriksaan Total Kuman Udara Dan Staphylococcus Aureus Di Ruang Rawat Inap Rumah Sakit X Kota Semarang.," *Jurnal Kesehatan Masyarakat Universitas Diponegoro*. vol. 1, no. 2, p. 18795, 2012.
- [2] F. Anwari and A. Mega, "Sakit Anwar Medika Sidoarjo.," pp. 31–38, 2017.



- [3] World Health Organisation, *Report on the burden of endemic health care-associated infection worldwide: Clean care is safer care.*, 2011.
- [4] Kementrian Kesehatan Republik Indonesia, PEDOMAN PENCEGAHAN DAN PENGENDALIAN INFEKSI DI FASILITAS PELAYANAN KESEHATAN., 2017.
- [5] Karen C. Carroll, J.S. Butel, and S.A. Morse, *Medical Microbiology. McGraw-Hill Companies*, New York, 2015.
- [6] R. Endriani, F. Andrini, and D. Alfina, "Pola Resistensi Bakteri Penyebab Infeksi Saluran Kemih (ISK) Terhadap Antibakteri di Pekanbaru.," *Jurnal Natur Indonesia*. vol. 12, no. 2, p. 130, 2012.
- [7] G.S. Nurjanah, A.I. Cahyadi, and S. Windria, "Kajian Pustaka: Resistensi Escherichia coli Terhadap Berbagai Macam Antibotik pada Hewan dan Manusia.," *Indonesia Medicus Veterinus*. vol. 9, no. November, pp. 967–980, 2020.
- [8] T. Wulansari, D. Sagita, and S. Pratama, "Uji Resistensi Antibiotik Terhadap Kultur Bakteri Enterobacter agglomerans di Ruang Intensive Care Unit (ICU) Rumah Sakit X Kota Jambi Antibiotic Resistance Test Against Enterobacter agglomerans Culture In The Intensive Care Unit (ICU) Hospital X Jamb.," vol. 6, no. 1, pp. 237–248, 2020.
- [9] A.S. Fahirah Arsal, "Deteksi dan Pola Kepekaan Antibiotik pada Extended Spectrum Beta Lactamase (Esbl) Eschericia Coli dari Sampel Urin Petugas Kesehatan di Rumah Sakit Ibnu Sina Makassar Tahun 2018.," UMI Medical Journal. vol. 3, no. 2, pp. 1–13, 2019.
- [10] N.E. Thomford, D.A. Senthebane, A. Rowe, et al., "Natural products for drug discovery in the 21st century: Innovations for novel drug discovery.," *International Journal of Molecular Sciences*. vol. 19, no. 6, p. 2018.
- [11] M. Adfa, "Isolasi Senyawa Flavonoid Aktif Berkhasiat Sitotoksik Dari Daun Kemuning (Murraya Panicullata L. Jack).," *Jurnal Gradien*. vol. 3, no. 2, pp. 262–266, 2007.
- [12] G.A. Kusuma, S.N.J. Longdong, and R.A. Tumbol, "Uji Daya Hambat Dari Ekstrak Tanaman Pacar Air (Impatiens balsamica L) Terhadap Pertumbuhan Bakteri Aeromonas hydrophila.," *jurnal ilmiah PS. agrobisnis perikanan UNSRAT, Manado.* pp. 9–12, 2014.
- [13] S.M.A. Budiana, N.S. Kojong, and D.S. Wewengkang, "Uji Aktivitas Antibakteri Ekstrak Etanol Bunga dan Biji Tanaman Pacar Air (Impatiens Balsamina L.) Terhadap Pertumbuhan Bakteri Staphylococcus aureus, Pseudomonas aeruginosa dan Escherichia coli Secara in-Vitro.," *Pharmacon.* vol. 4, no. 4, pp. 214–223, 2015.
- [14] D.A. Talan, S.S. Takhar, A. Krishnadasan, et al., "Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase– Producing Escherichia coli Infections in Patients

with Pyelonephritis, United States.," *Emerging Infectious Diseases*. vol. 22, no. 9, pp. 1594–1603, 2017.

- [15] S.Y.C. Tong, J.S. Davis, E. Eichenberger, T.L. Holland, and V.G. Fowler, "Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management.," *Clinical Microbiology Reviews*. vol. 28, no. 3, pp. 603–661, 2015.
- [16] Y. Cong, S. Yang, and X. Rao, "Vancomycin resistant Staphylococcus aureus infections: A review of case updating and clinical features.," *Journal of Advanced Research*. vol. 21, pp. 169–176, 2020.
- [17] S.E. Majowicz, E. Scallan, A. Jones-Bitton, et al., "Global incidence of human shiga toxin-producing escherichia coli infections and deaths: A systematic review and knowledge synthesis.," *Foodborne Pathogens and Disease*. vol. 11, no. 6, pp. 447– 455, 2014.
- [18] J.E. Ross, N.E. Scangarella-Oman, R.K. Flamm, and R.N. Jones, "Determination of disk diffusion and MIC quality control guidelines for GSK2140944, a novel bacterial type II topoisomerase inhibitor antimicrobial agent.," *Journal of Clinical Microbiology*. vol. 52, no. 7, pp. 2629–2632, 2014.
- [19] O. Gefen, B. Chekol, J. Strahilevitz, and N.Q. Balaban, "TDtest: Easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assay.," *Scientific Reports*. vol. 7, no. February, pp. 1–9, 2017.
- [20] M. Balouiri, M. Sadiki, and S.K. Ibnsouda, "Methods for in vitro evaluating antimicrobial activity: A review.," *Journal of Pharmaceutical Analysis*. vol. 6, no. 2, pp. 71–79, 2016.
- [21] W. van den Bijllaardt, A.G. Buiting, J.W. Mouton, and A.E. Muller, "Shortening the incubation time for antimicrobial susceptibility testing by disk diffusion for Enterobacteriaceae: How short can it be and are the results accurate?," *International Journal of Antimicrobial Agents*. vol. 49, no. 5, pp. 631–637, 2017.